-
Tytuł:
-
Factors determining the actual received dose intensity in a program of multicyclic dose-intensive alternating chemotherapy with sequential stem cell support.
-
Autorzy:
-
Pérez-Calvo J; Department of Oncology and Cell Therapy Area, Clínica Universitaria de Navarra, Pamplona, Spain. />Martínez-Aguillo M
García-Rayo S
Ramón y Cajal T
Santisteban M
Ordóñez JM
Inogés S
Subirá ML
Martín-Algarra S
Brugarolas A
-
Źródło:
-
Acta haematologica [Acta Haematol] 2001; Vol. 105 (3), pp. 137-42.
-
Typ publikacji:
-
Clinical Trial; Journal Article
-
Język:
-
English
-
Imprint Name(s):
-
Original Publication: Basel, Karger.
-
MeSH Terms:
-
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Breast Neoplasms/*therapy
Hematopoietic Stem Cell Transplantation/*standards
Ovarian Neoplasms/*therapy
Stem Cells/*immunology
Adult ; Antigens, CD34/analysis ; Cell Count ; Cisplatin/administration & dosage ; Dose-Response Relationship, Drug ; Drug Administration Schedule ; Etoposide/administration & dosage ; Female ; Hematopoietic Stem Cell Transplantation/methods ; Humans ; Ifosfamide/administration & dosage ; Immunomagnetic Separation ; Middle Aged ; Models, Biological ; Paclitaxel/administration & dosage ; Time Factors ; Transplantation, Autologous ; Treatment Outcome
-
Substance Nomenclature:
-
0 (Antigens, CD34)
6PLQ3CP4P3 (Etoposide)
P88XT4IS4D (Paclitaxel)
Q20Q21Q62J (Cisplatin)
UM20QQM95Y (Ifosfamide)
-
Entry Date(s):
-
Date Created: 20010721 Date Completed: 20010906 Latest Revision: 20171101
-
Update Code:
-
20240104
-
DOI:
-
10.1159/000046555
-
PMID:
-
11463986
-
Dose intensity has been related to clinical outcome in several solid tumors. We studied the influence of clinical and cellular parameters on dose intensity received in a series of 53 patients with metastatic breast cancer or advanced ovarian cancer. They received courses of cisplatin 120 mg/m(2) plus etoposide 600 mg/m(2) alternating every 14 days with ifosfamide 8 g/m(2) plus paclitaxel 200--350 mg/m(2). Blood stem cell support was administered after every course except for the first one. Patients with excellent mobilization underwent immunomagnetic selection of CD34+ cells. We found a significant inverse correlation between the CD34+ cell dose infused and the delay for the administration of the next cycle. A CD34+ cell dose between 1.5 and 5 x 10(6)/kg per cycle was found to be feasible and was followed by a median delay of 1 day (not different from doses above 5 x 10(6)/kg). Three factors independently predicted the actually received dose intensity in a multiple regression model (R(2) = 0.4): previous autologous transplantation, eligibility for immunomagnetic selection (excellent response to mobilization) and median CD34+ cell dose received along the treatment.
(Copyright 2001 S. Karger AG, Basel)